Nivalis Therapeutics Inc. (NASDAQ:NVLS)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued on Tuesday.

Other analysts also recently issued research reports about the company. Cowen and Company reiterated a “buy” rating on shares of Nivalis Therapeutics in a research note on Monday, August 1st. Piper Jaffray Cos. reiterated a “buy” rating and set a $16.00 price target on shares of Nivalis Therapeutics in a research note on Tuesday, August 30th. Zacks Investment Research upgraded Nivalis Therapeutics from a “sell” rating to a “buy” rating and set a $8.50 price target on the stock in a research note on Thursday, October 20th. Stifel Nicolaus downgraded Nivalis Therapeutics from a “buy” rating to a “hold” rating and dropped their price target for the company from $16.00 to $3.25 in a research note on Tuesday. Finally, Raymond James Financial Inc. downgraded Nivalis Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $9.60.

Analyst Recommendations for Nivalis Therapeutics (NASDAQ:NVLS)

Nivalis Therapeutics (NASDAQ:NVLS) traded down 59.7952% during mid-day trading on Tuesday, hitting $2.5128. The company had a trading volume of 3,279,286 shares. The company has a 50-day moving average price of $6.46 and a 200 day moving average price of $5.84. Nivalis Therapeutics has a 12 month low of $2.51 and a 12 month high of $9.46. The firm’s market capitalization is $39.06 million.

Nivalis Therapeutics (NASDAQ:NVLS) last posted its quarterly earnings results on Monday, November 7th. The company reported ($0.48) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.11. Equities analysts forecast that Nivalis Therapeutics will post ($2.10) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Nivalis Therapeutics Inc. (NVLS) Given Buy Rating at HC Wainwright” was originally published by Daily Political and is owned by of Daily Political. If you are reading this piece on another site, it was stolen and republished in violation of United States & international copyright legislation. The correct version of this piece can be read at http://www.dailypolitical.com/2016/11/29/nivalis-therapeutics-inc-nvls-given-buy-rating-at-hc-wainwright.html.

In other news, EVP David Malcom Rodman sold 5,820 shares of the business’s stock in a transaction dated Tuesday, October 4th. The stock was sold at an average price of $7.96, for a total value of $46,327.20. Following the completion of the transaction, the executive vice president now owns 18,056 shares of the company’s stock, valued at approximately $143,725.76. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 3.00% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in NVLS. Bank of New York Mellon Corp boosted its position in Nivalis Therapeutics by 7.8% in the third quarter. Bank of New York Mellon Corp now owns 16,494 shares of the company’s stock worth $134,000 after buying an additional 1,189 shares during the last quarter. Spark Investment Management LLC acquired a new position in Nivalis Therapeutics during the third quarter worth $145,000. Paloma Partners Management Co acquired a new position in Nivalis Therapeutics during the second quarter worth $105,000. Endurant Capital Management LP boosted its position in Nivalis Therapeutics by 29.8% in the third quarter. Endurant Capital Management LP now owns 85,412 shares of the company’s stock worth $694,000 after buying an additional 19,629 shares during the last quarter. Finally, Sphera Funds Management LTD. acquired a new position in Nivalis Therapeutics during the third quarter worth $1,664,000. 79.26% of the stock is owned by institutional investors.

Nivalis Therapeutics Company Profile

Nivalis Therapeutics, Inc is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases.

5 Day Chart for NASDAQ:NVLS

Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.